Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2011 Apr 12;29(17):3341-55. doi: 10.1016/j.vaccine.2010.08.002. Epub 2010 Aug 14.

TLR-based immune adjuvants.

Author information

1
Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, United States.

Abstract

This work describes the nature and strength of the immune response induced by various Toll-like receptor ligands and their ability to act as vaccine adjuvants. It reviews the various ligands capable of triggering individual TLRs, and then focuses on the efficacy and safety of those agents for which clinical results are available.

PMID:
20713100
PMCID:
PMC3000864
DOI:
10.1016/j.vaccine.2010.08.002
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center